source
- AI drives faster drug development and reshapes biopharma manufacturing facilitiesAI is speeding up the identification of drug candidates, turning years of laboratory work into months by analyzing large biological datasets and accelerating early‑stage development. This accelera…
- Leerink analyst downgrades Bristol Myers over pipeline concernsA Leerink analyst signaled new bearishness on Bristol Myers Squibb, downgrading the company's stock rating. Analyst David Risinger moved the rating from outperform to a lower stance, saying he is…